• SGI-1027 and Everolimus in Renal Cancer

  2026-08-26

  A 2024 Advanced Science study identifies SGI-1027 as an inducer of cytoplasmic vacuolation and methuosis in renal cancer cells, and shows that it cooperates with everolimus to suppress malignant phenotypes. The combination links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a mechanistic framework for investigating everolimus resistance in renal cell carcinoma.

• uPAR–uPA Inhibition and Breast Cancer Metastasis

  2026-08-25

  Mani and colleagues combined chemical synthesis, direct binding assays, cellular invasion models, pharmacokinetics, and a mouse metastasis study to evaluate compound 4 as an inhibitor of the uPAR–uPA interaction. The work connects sub-micromolar receptor binding with reduced tumor-cell invasion and lung metastasis, while also identifying pharmacokinetic properties that guide further optimization.

• EHEC Delays Precocious Puberty in Danazol Rat Models

  2026-08-25

  A 2025 study evaluated an Eclipta prostrata–Hordeum vulgare extract complex in rat models of precocious puberty induced by Danazol or a high-fat diet. The complex delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation without altering body weight, supporting further investigation of hypothalamic–pituitary–gonadal axis modulation.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-24

  A 2025 GeroScience study develops a drug-sensitized Saccharomyces cerevisiae platform that detects TOR inhibitors at substantially lower concentrations than conventional yeast assays. The system distinguishes TOR1-dependent growth inhibition, identifies activity from established and previously unrecognized compounds, and provides a practical screening framework while clarifying why negative results for compounds such as canagliflozin should not be interpreted as evidence against their established non-TOR mechanisms.

• EHEC Prevents Precocious Puberty in Danazol Rat Models

  2026-08-24

  A 2025 study tested an Eclipta prostrata–Hordeum vulgare extract complex in two rat models of precocious puberty induced by Danazol or a high-fat diet. The complex delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation without altering body weight, supporting further investigation of hypothalamic–pituitary–gonadal axis modulation.

• FITC Goat Anti-Rabbit IgG: Translational Insight

  2026-08-23

  A thought-leadership guide to using fluorescent secondary-antibody workflows to strengthen mechanistic validation of lycopene protection against DON-induced intestinal barrier dysfunction and NLRP3 activation.

• BCLAF1–YTHDF2–SIX1 Axis in ESCC

  2026-08-22

  The reference study identifies a post-transcriptional mechanism in which BCLAF1 promotes esophageal squamous cell carcinoma by weakening YTHDF2-dependent degradation of m6A-modified SIX1 mRNA. Its integrated clinical, biochemical, transcriptomic, and in vivo evidence connects RNA stability with glycolysis, invasion, and tumor progression, providing a framework for mechanistic cancer research.

• 2'3'-cGAMP (sodium salt): Assay Guide

  2026-08-22

  This scenario-based guide explains how 2'3'-cGAMP (sodium salt), SKU B8362, can improve the design, handling, and interpretation of STING-pathway experiments linked to viability, proliferation, and cytotoxicity assays. It combines product specifications with mechanistic evidence on cGAMP hydrolysis by tumor-derived exosomal ENPP1.

• PRV Infection, NF-κB, and AIM2 Signaling

  2026-08-21

  The reference study identifies a coordinated TLR2/TLR3/TLR4/TLR5–NF-κB response and AIM2 inflammasome pathway that drives cytokine production during pseudorabies virus infection in mice. Its main contribution is linking NF-κB-dependent cytokine priming with AIM2, ASC, caspase-1, and GSDMD-dependent cytokine release, while showing that this inflammatory program contributes to antiviral host defense.

• Cyclopamine: Translating Hedgehog Biology

  2026-08-20

  A translational perspective on Cyclopamine as a Smoothened-directed Hedgehog signaling inhibitor, connecting developmental biology, cancer research, assay design, and strategic decision-making.

• Retinoic Acid and Nutrient Restriction Trigger SSC Meiosis

  2026-08-20

  A Methods in Molecular Biology chapter by Zhang and Wang presents a culture strategy in which retinoic acid and nutrient restriction work together to initiate meiotic prophase I in long-term mouse spermatogonial stem cells. The approach addresses a persistent barrier in germline culture and provides a practical framework for studying meiotic entry without assuming that complete spermatogenesis has been achieved in vitro.

• Cefotaxime as a Probe of AMR Transmission

  2026-08-19

  Cefotaxime can do more than benchmark antibacterial activity. Used alongside genotype, plasmid-mobility, and infection-model data, it helps translational researchers connect beta-lactam antibiotic mechanism with the evolving architecture of antimicrobial resistance.

• JTW, Coptisine, and SIRT1 in PCOS Mitochondria

  2026-08-19

  A 2025 Phytomedicine study identifies suppression of SIRT1 ubiquitination as a mechanistic basis for the anti-PCOS activity of Jiao-tai-wan and its constituent coptisine. Using DHEA-induced PCOS rats and primary theca cells, the authors connect SIRT1 protein stability with mitochondrial cholesterol import, StAR localization, and abnormal ovarian steroidogenesis.

• PDK4-IN-1 Hydrochloride: Mechanism & Uses

  2026-08-18

  PDK4-IN-1 hydrochloride is a selective, orally active pyruvate dehydrogenase kinase 4 inhibitor for research on PDH activation and mitochondrial energy metabolism. Product specifications and peer-reviewed findings support its use in in vitro metabolism studies and animal models, while distinguishing vendor-reported properties from evidence for lead compound 8c.

• GDC-0994: Practical ERK1/2 Assay Guidance

  2026-08-18

  This scenario-based guide explains how GDC-0994 (SKU B5817) can support mechanistic studies of ERK-driven proliferation, viability, and cholestatic injury. It covers target engagement, solvent handling, dose design, orthogonal readouts, and practical criteria for selecting a reliable research reagent.

8485 records 1/566 page Next 12345 下5页 Last page